BEAM Beam Therapeutics Inc
Company Analysis
Latest News
Farallon Capital Discloses New $241.51M Stake in Beam Therapeutics
In a recent filing, Farallon Capital Management revealed it had established a significant new position in Beam Therapeutics (BEAM), a biotechnology company...
🔴 Beam Therapeutics falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Beam Therapeutics is trading 10.1% up today as biotech shares rally
Beam Therapeutics is trading at $31.20 (+10.13%) as biotechnology shares rally, with XBI up 2.06% during the regular session. - No fresh company-specific...
🟢 Beam Therapeutics rises 4.9% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🔴 Beam Therapeutics is trading 4.5% down today as elevated Treasury yields pressure growth valuations
Beam Therapeutics is trading now at $28.41 (-4.54%) amid broader risk-off pressure on growth stocks. • The Nasdaq Composite is down 0.53%, while elevated...
🟢 Beam Therapeutics is trading 4.56% up today — with no specific catalyst identified
Beam Therapeutics is trading 4.56% up at $29.68, with no specific catalyst identified for the intraday rebound. - No reliable company-specific announcement,...
🔴 Beam Therapeutics falls 5.6% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Beam Therapeutics is trading 7.3% up today as Moderna’s positive cancer-vaccine results lift biotech
Beam Therapeutics is trading 7.3% up now at $28.51, most likely reflecting biotech-sector momentum after Moderna’s positive personalized cancer-vaccine trial...
🟢 Beam Therapeutics is trading 5% up in pre-market
Beam Therapeutics is trading 5.24% up now at $28.11 versus the August 12 close of $26.71; no fresh company-specific announcement explaining the August 13...
🔴 Beam Therapeutics is trading 4.1% down today after Q2 earnings miss and BofA price target trim
Beam Therapeutics is trading 4.1% down at $27.20 as investors digest a Q2 earnings miss and a price target reduction from Bank of America. • The decline...
🟢 Beam Therapeutics is trading 4.1% up today on extended cash runway and clinical updates
Beam Therapeutics is trading 4.1% up now at $26.98 after the company provided a positive financial outlook and clinical milestones that outweighed...
Beam Therapeutics' second quarter revenue and EPS miss estimates while the company advances its pivotal BEAM-302 trial.
Beam Therapeutics reported a second quarter net loss of $122.7 million, or $1.18 per share, on collaboration revenue of $0.5 million. The company highlighted...
Beam Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
For the second quarter of 2026, analysts anticipate Beam Therapeutics will report revenue of $315.40 million and earnings per share of $1.00, while the current...
🔴 Beam Therapeutics is trading 4.1% down today amid broader biotech sector weakness
Beam Therapeutics is trading 4.1% down at $25.40 amid a sharp pullback in biotechnology stocks. • The move appears tied to broader sector weakness, as the...
🟢 Beam Therapeutics is trading 4.2% up today on broader risk-on sentiment and easing macro tensions
Beam Therapeutics is trading at $26.11 (+4.15%) as broader risk-on sentiment and easing macroeconomic tensions support a rotation back into growth assets. •...
🟢 Beam Therapeutics is trading 4.4% up today on broader risk-on sentiment and easing macro tensions
Beam Therapeutics is trading at $26.20 (4.4%) up today, rebounding from last week's biotech sector weakness as broader market sentiment improves. • The stock...
Beam Therapeutics to Present BEAM-302 Data for Alpha-1 Antitrypsin Deficiency
Beam Therapeutics will present updated Phase 1/2 clinical data for BEAM-302, its lead program for alpha-1 antitrypsin deficiency (AATD). The oral presentation...
🟢 Beam Therapeutics is trading 4% up today after snapping an eight-session slide
Beam Therapeutics is trading 4% up today at $27.39 as the stock stages a technical bounce following an extended period of selling pressure. • Shares are...
🔴 Beam Therapeutics is trading 4% down today as profit-taking extends multi-day slide
Beam Therapeutics is trading 4% down at $26.42 as profit-taking and fading momentum continue to weigh on the stock during an extended pullback. • The decline...
🟢 Beam Therapeutics is trading 4.5% up today on a technical rebound following sector weakness
Beam Therapeutics is trading at $32.40 (+4.52%) in pre-market as the stock stages a technical rebound following a period of broader biotech sector weakness. •...